MA35851B1 - Nanoparticules comprenant des matériaux métalliques et d'oxydes d'hafnium, leur préparation et utilisations - Google Patents

Nanoparticules comprenant des matériaux métalliques et d'oxydes d'hafnium, leur préparation et utilisations

Info

Publication number
MA35851B1
MA35851B1 MA37185A MA37185A MA35851B1 MA 35851 B1 MA35851 B1 MA 35851B1 MA 37185 A MA37185 A MA 37185A MA 37185 A MA37185 A MA 37185A MA 35851 B1 MA35851 B1 MA 35851B1
Authority
MA
Morocco
Prior art keywords
nanoparticles
hafnium oxide
metallic
preparation
oxide materials
Prior art date
Application number
MA37185A
Other languages
English (en)
Inventor
Agnès Pottier
Laurent Levy
Marie-Edith Meyre
Original Assignee
Nanobiotix
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanobiotix filed Critical Nanobiotix
Publication of MA35851B1 publication Critical patent/MA35851B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Dispersion Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Powder Metallurgy (AREA)

Abstract

Cette invention concerne de nouvelles nanoparticules qui peuvent être avantageusement utilisées dans le secteur de la santé à titre d'agents diagnostiques et/ou thérapeutiques. Les nanoparticules selon l'invention comprennent un matériau métallique au moins en partie recouvert d'un matériau d'oxyde d'hafnium ou noyé dans celui-ci. Comparativement aux produits existants, ces nanoparticules offrent un remarquable rapport bénéfice-risque. Plus spécifiquement, ces nanoparticules potentialisent l'efficacité des nanoparticules métalliques connues. Elles conservent naturellement les propriétés intrinsèques du métal et sont désormais, en plus, utilisables sans danger chez un mammifère, en particulier, chez l'homme. Cette invention concerne également des procédés de production desdites nanoparticules, des compositions les contenant, et leurs utilisations.
MA37185A 2011-12-16 2014-07-09 Nanoparticules comprenant des matériaux métalliques et d'oxydes d'hafnium, leur préparation et utilisations MA35851B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11193968 2011-12-16
PCT/EP2012/075731 WO2013087920A1 (fr) 2011-12-16 2012-12-17 Nanoparticules comprenant des matériaux métalliques et d'oxydes d'hafnium, leur préparation et utilisations

Publications (1)

Publication Number Publication Date
MA35851B1 true MA35851B1 (fr) 2014-12-01

Family

ID=48611880

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37185A MA35851B1 (fr) 2011-12-16 2014-07-09 Nanoparticules comprenant des matériaux métalliques et d'oxydes d'hafnium, leur préparation et utilisations

Country Status (16)

Country Link
US (1) US10945965B2 (fr)
EP (1) EP2790682B1 (fr)
JP (1) JP6042450B2 (fr)
KR (1) KR102025743B1 (fr)
CN (1) CN104093401B (fr)
AU (1) AU2012351537B2 (fr)
BR (1) BR112014014412A2 (fr)
CA (1) CA2857260C (fr)
EA (1) EA029635B1 (fr)
HK (1) HK1203353A1 (fr)
IL (1) IL233035B (fr)
MA (1) MA35851B1 (fr)
MX (1) MX362089B (fr)
PL (1) PL2790682T3 (fr)
SG (1) SG11201403096VA (fr)
WO (1) WO2013087920A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3494974B1 (fr) 2011-07-08 2023-10-18 The University of North Carolina at Chapel Hill Nanoparticules de métal-bisphosphonate pour thérapie anticancéreuse et imagerie, ainsi que pour traiter des troubles des os
MX362089B (es) 2011-12-16 2019-01-07 Nanobiotix Nanopartículas que comprenden materiales metálicos y óxido de hafnio, preparación y usos de los mismos.
PL2948179T3 (pl) * 2013-01-25 2019-10-31 Nanobiotix Kompozycje zawierające nanocząstki tlenku hafnu(iv) lub tlenku renu(iv) w połączeniu z promieniowaniem jonizującym do leczenia nowotworu
WO2014202723A1 (fr) * 2013-06-20 2014-12-24 Nanobiotix Compositions et procédés pour une utilisation en diagnostic médical
US10806694B2 (en) * 2014-10-14 2020-10-20 The University Of Chicago Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof
WO2016061256A1 (fr) 2014-10-14 2016-04-21 The University Of Chicago Nanoparticules pour thérapie photodynamique, thérapie photodynamique induite par rayons x, radiothérapie, chimiothérapie, immunothérapie, et toute combinaison de celles-ci
CN107708668A (zh) * 2015-05-28 2018-02-16 纳米生物技术公司 用作治疗性疫苗的纳米粒子
US11389536B2 (en) * 2015-07-17 2022-07-19 BioCurity Pharmaceuticals Inc. Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent
US9607952B1 (en) * 2015-10-30 2017-03-28 International Business Machines Corporation High-z oxide nanoparticles embedded in semiconductor package
JP7090034B2 (ja) 2016-05-20 2022-06-23 ザ ユニバーシティ オブ シカゴ 化学療法、標的療法、光線力学療法、免疫療法及びそれらの任意の組み合わせのためのナノ粒子
WO2018114945A1 (fr) * 2016-12-21 2018-06-28 Nanobiotix Nanoparticules destinées à être utilisées pour traiter un trouble neuronal
CN111194232B (zh) 2017-08-02 2023-01-31 芝加哥大学 纳米级金属有机层和金属有机纳米片
JP7116563B2 (ja) * 2018-03-16 2022-08-10 株式会社日本触媒 複合粒子
CN109010828B (zh) * 2018-10-12 2020-10-20 中国科学院高能物理研究所 一种二硫化钼/二氧化铪的复合纳米材料、其制备方法及用途
CN112675305B (zh) * 2021-01-22 2023-05-23 中国科学院深圳先进技术研究院 用于肿瘤治疗的双亲性分子自组装纳米药物及制备方法和用途
WO2024126383A1 (fr) 2022-12-12 2024-06-20 Nanobiotix (Nanobiotix S.A.) Nouvelles nanoparticules d'oxyde métallique et compositions de celles-ci destinées à être utilisées en tant que radioactivateurs ou pour visualiser un tissu biologique

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4280918A (en) 1980-03-10 1981-07-28 International Business Machines Corporation Magnetic particle dispersions
US4672040A (en) 1983-05-12 1987-06-09 Advanced Magnetics, Inc. Magnetic particles for use in separations
US4770183A (en) 1986-07-03 1988-09-13 Advanced Magnetics Incorporated Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US6099457A (en) * 1990-08-13 2000-08-08 Endotech, Inc. Endocurietherapy
US5370901A (en) 1991-02-15 1994-12-06 Bracco International B.V. Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients
JPH05209072A (ja) * 1992-01-29 1993-08-20 Japan Synthetic Rubber Co Ltd 基材の表面処理方法
EP0645048A1 (fr) 1992-06-08 1995-03-29 BioQuest Incorporated Preparation de particules inorganiques a dimensions reglables utiles dans des separations, comme commutateurs moleculaires magnetiques et comme liposomes inorganiques dans des applications medicales
AU4778893A (en) 1992-07-21 1994-02-14 General Hospital Corporation, The System of drug delivery to the lymphatic tissues
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
EP0971692B1 (fr) 1997-03-07 2003-03-05 Max-Delbrück-Centrum Für Molekulare Medizin Magnetosomes specifiques, leur procede de production et leur utilisation
DE19716732C2 (de) 1997-03-07 1999-03-25 Max Delbrueck Centrum Spezifische Magnetosomen, Verfahren zu ihrer Herstellung und ihre Verwendung
DE19726282A1 (de) 1997-06-20 1998-12-24 Inst Neue Mat Gemein Gmbh Nanoskalige Teilchen mit einem von mindestens zwei Schalen umgebenen eisenoxid-haltigen Kern
US6726925B1 (en) 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
US6200598B1 (en) 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
WO2000006244A2 (fr) * 1998-07-30 2000-02-10 Hainfeld James F Particules metalliques de chargement dans des vesicules membranaires cellulaires et particule metallique utilisee pour l'imagerie et la therapie
AU4305101A (en) 1999-11-22 2001-06-04 Research Foundation Of The State University Of New York, The Magnetic nanoparticles for selective therapy
AU3679801A (en) 2000-02-08 2001-08-20 Rice University Optically-active nanoparticles for use in therapeutic and diagnostic methods
AU2002259107B2 (en) 2001-04-30 2006-10-26 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
DE10154016B4 (de) 2001-10-26 2004-02-12 Berlin Heart Ag Magnetflüssigkeit und Verfahren zur ihrer Herstellung
AU2002351240A1 (en) 2002-03-08 2003-09-22 James Hainfeld Gold nanoparticles used for x-rays imaging
US7769423B2 (en) 2002-09-11 2010-08-03 Duke University MRI imageable liposomes for the evaluation of treatment efficacy, thermal distribution, and demonstration of dose painting
US20030125283A1 (en) 2002-09-16 2003-07-03 Gatenby Robert A. Therapy of proliferative disorders by direct irradiation of cell nuclei with tritiated nuclear targetting agents
US7235228B2 (en) 2003-04-15 2007-06-26 The United States Of America As Represented By The Secretary Of The Navy Fluorescent-magnetic nanoparticles with core-shell structure
US20050084869A1 (en) 2003-10-20 2005-04-21 Sung Hyun Kim Novel composition and methods for the diagnosis of lung cancer
WO2005046733A1 (fr) 2003-11-17 2005-05-26 Philips Intellectual Property & Standards Gmbh Agent de contraste pour des techniques d'imagerie medicale, et son utilisation
CA2547024C (fr) 2003-12-22 2013-12-17 Bracco Research Sa Systeme de microvesicule remplie de gaz pour l'imagerie de contraste
JP4895151B2 (ja) 2004-02-27 2012-03-14 日立金属株式会社 鉄系ナノサイズ粒子およびその製造方法
FR2869803B1 (fr) 2004-05-10 2006-07-28 Nanobiotix Sarl Particules activables, preparation et utilisations
US20050260137A1 (en) 2004-05-18 2005-11-24 General Electric Company Contrast agents for magnetic resonance imaging
US20070031337A1 (en) 2004-06-22 2007-02-08 Reinhard Schulte Nanoparticle enhanced proton computed tomography and proton therapy
GB2415374A (en) 2004-06-25 2005-12-28 Leuven K U Res & Dev Targeted delivery of biologically active substances using iron oxide/gold core-shell nanoparticles
WO2006037081A2 (fr) * 2004-09-28 2006-04-06 The Regents Of The University Of California Radiosensibiliseurs a base de nanoparticules
WO2006051732A1 (fr) 2004-11-10 2006-05-18 Konica Minolta Medical & Graphic, Inc. Préparation pharmaceutique contenant des particules magnétiques revêtues et procédé de fabrication idoine, et système de thérapie de diagnostic
US20070092927A1 (en) 2005-06-13 2007-04-26 University Of Dayton Photocatalytic particles with directed and controlled redox activity
US20090304587A1 (en) 2005-11-01 2009-12-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Biodegradable composite for internal local radiotherapy
US20070098642A1 (en) 2005-11-02 2007-05-03 General Electric Company Nanoparticle-based imaging agents for X-ray/computed tomography
KR100745744B1 (ko) * 2005-11-11 2007-08-02 삼성전기주식회사 나노 입자 코팅 방법
WO2007122956A1 (fr) 2006-03-24 2007-11-01 Toto Ltd. Particules complexes d'oxyde de titane, dispersion des particules et procédé pour la production des particules
JP2009536151A (ja) 2006-03-30 2009-10-08 富士フイルム株式会社 ナノ粒子
EP1852107A1 (fr) 2006-04-19 2007-11-07 Nanobiotix Compositions contenant des nanoparticules magnétiques et leur utilisation
RU2009104312A (ru) 2006-07-10 2010-08-20 Конинклейке Филипс Электроникс Н.В. (Nl) Наночастицы типа "ядро-оболочка" для терапии и диагностических целей
DE102006041495A1 (de) 2006-08-29 2008-03-20 Friedrich-Schiller-Universität Jena Substanzgemisch zur lokalen Deposition von Magnetpartikeln in einem Medium, insbesondere in tumorbefallenem organischem Gewebe, sowie Applikationskit zur Verabreichung
NO329127B1 (no) 2006-09-12 2010-08-30 Epitarget As Sporbart partikulaert materiale for legemiddelavlevering omfattende et matriseeller membranmateriale, et legemiddel, og et T1- og et T2*- magnetisk resonanskontrastmiddel
NO20064315L (no) 2006-09-22 2008-03-24 Epitarget As T1 MRI-sporbare medikamentavleveringspartikler and anvendelse derav
EP1920784A1 (fr) 2006-11-13 2008-05-14 Koninklijke Philips Electronics N.V. Sensibilisateurs de radiation pour la thérapie par rayonnements ionisants et pour l'imagerie
US20090004258A1 (en) 2007-06-27 2009-01-01 National Health Research Institutes Drug Release from Thermosensitive Liposomes by Applying an Alternative Magnetic Field
JP2009067613A (ja) * 2007-09-11 2009-04-02 Fujifilm Corp コア−シェル型金属酸化物微粒子及びその製造方法
US20120176016A1 (en) * 2007-09-28 2012-07-12 General Electric Company Core-shell particulates, articles, and method of making
FR2922106B1 (fr) 2007-10-16 2011-07-01 Univ Claude Bernard Lyon Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants.
EP2067485A1 (fr) 2007-12-07 2009-06-10 Koninklijke Philips Electronics N.V. Transporteur de médicament fournissant un contraste amélioré pour l'IRM
EP2231765A2 (fr) 2007-12-21 2010-09-29 University Of Guelph Nanoparticules de polysaccharide
EP2242539B1 (fr) 2008-01-16 2015-04-01 Nanospectra Biosciences, Inc. Nanoparticules déclenchant une hyperthermie ciblée afin d'améliorer l'efficacité de radiothérapie
DE102008008522A1 (de) 2008-02-11 2009-08-13 Magforce Nanotechnologies Ag Implantierbare Nanopartikel-enthaltende Produkte
WO2009142754A1 (fr) 2008-05-22 2009-11-26 Goverment Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Conjugués dendritiques et procédés associés
EP2130553A1 (fr) 2008-06-05 2009-12-09 Nanobiotix Nanoparticules inorganiques de haute densité pour détruire des cellules in-vivo
GB0811300D0 (en) * 2008-06-19 2008-07-30 Syngenta Participations Ag Methods of controlling neonicotinoid resistant insects
US20130023714A1 (en) 2008-10-26 2013-01-24 Board Of Regents, The University Of Texas Systems Medical and Imaging Nanoclusters
EP2275137A1 (fr) 2009-07-10 2011-01-19 Nanobiotix Nanoparticules métalliques, leur préparation et utilisations
EP2305310A1 (fr) 2009-09-25 2011-04-06 Asociación Centro de Investigación Cooperativa en Biomateriales - CIC biomaGUNE Glyconanoparticules magnétiques à revêtement en or fonctionnalisées pour une utilisation en tant qu'agents de diagnostic et de traitement
GB0921596D0 (en) 2009-12-09 2010-01-27 Isis Innovation Particles for the treatment of cancer in combination with radiotherapy
WO2011102407A1 (fr) 2010-02-17 2011-08-25 国立大学法人神戸大学 Agent de radiothérapie
EP2555800B1 (fr) 2010-04-05 2018-03-21 Nanospectra Biosciences, Inc. Amélioration d'une thérapie par rayonnement par nanoparticules ciblées à z élevé
GB201009455D0 (en) 2010-06-04 2010-07-21 King S College London Nanoparticles and their uses in molecular imaging
EP2670393B8 (fr) 2011-01-31 2016-10-05 Nanobiotix Procédé de surveillance de la libération par des liposomes d'un produit d'intérêt au moyen de nanoparticules superparamagnétiques
PL2670394T3 (pl) 2011-01-31 2019-03-29 Nanobiotix Układy do dostarczania nanocząstek, ich otrzymywanie i zastosowania
MX362089B (es) 2011-12-16 2019-01-07 Nanobiotix Nanopartículas que comprenden materiales metálicos y óxido de hafnio, preparación y usos de los mismos.
PL2948179T3 (pl) 2013-01-25 2019-10-31 Nanobiotix Kompozycje zawierające nanocząstki tlenku hafnu(iv) lub tlenku renu(iv) w połączeniu z promieniowaniem jonizującym do leczenia nowotworu
US20140219926A1 (en) 2013-02-01 2014-08-07 The Trustees Of Dartmouth College Biodegradable Iron Oxide Nanoparticle Gel for Tumor Bed Therapy
AU2014273043B2 (en) 2013-05-30 2019-02-07 Curadigm Sas Pharmaceutical composition, preparation and uses thereof
WO2014202723A1 (fr) 2013-06-20 2014-12-24 Nanobiotix Compositions et procédés pour une utilisation en diagnostic médical
EP3010552B1 (fr) 2013-06-20 2019-04-17 Nanobiotix Compositions pour une utilisation en oncologie
EP2886128A1 (fr) 2013-12-20 2015-06-24 Nanobiotix Compositions pharmaceutiques comportant des nanoparticules, leur préparation et leur utilisation

Also Published As

Publication number Publication date
PL2790682T3 (pl) 2019-08-30
SG11201403096VA (en) 2014-07-30
CN104093401A (zh) 2014-10-08
EA201491199A1 (ru) 2014-11-28
WO2013087920A1 (fr) 2013-06-20
US20140335015A1 (en) 2014-11-13
KR102025743B1 (ko) 2019-09-26
MX362089B (es) 2019-01-07
MX2014007131A (es) 2014-09-04
IL233035A0 (en) 2014-07-31
CA2857260A1 (fr) 2013-06-20
JP2015509079A (ja) 2015-03-26
HK1203353A1 (en) 2015-10-30
BR112014014412A2 (pt) 2017-06-13
EP2790682B1 (fr) 2019-03-20
JP6042450B2 (ja) 2016-12-14
EP2790682A1 (fr) 2014-10-22
CN104093401B (zh) 2018-06-29
CA2857260C (fr) 2019-10-15
US10945965B2 (en) 2021-03-16
IL233035B (en) 2018-02-28
NZ625848A (en) 2015-04-24
AU2012351537B2 (en) 2017-03-02
EA029635B1 (ru) 2018-04-30
AU2012351537A1 (en) 2014-07-24
KR20140108685A (ko) 2014-09-12

Similar Documents

Publication Publication Date Title
MA35851B1 (fr) Nanoparticules comprenant des matériaux métalliques et d'oxydes d'hafnium, leur préparation et utilisations
MA33294B1 (fr) Procédé destiné à la production de poudres de nanoparticules et de microparticules à usage commercial
MA34286B1 (fr) Compositions pharmaceutiques et procédés pour les fabriquer
MA33297B1 (fr) Production de nanoparticules encapsulées à des fractions volumiques élevées
CL2016002585A1 (es) Inmunoconjugado que comprende una proteína de unión a antígeno que se une a antígeno de maduración de linfocitos b (bcma) y un agente citotóxico, composición farmacéutica y su uso (divisional solicitud 201303373)
MY159576A (en) Oral care composition to reduce or eliminate dental sensitivity
BRPI0705488A (pt) composição nanoparticulada estável, métodos de preparar a mesma e de prevenir e/ou tratar uma infecção bacteriana, composição farmacêutica, e, forma de dosagem
MX2018012500A (es) Formas de dosificacion de liberacion modificada disuasivas de abuso.
WO2006108405A3 (fr) Conjugues de nanoparticules et d'agents actifs
MA42859B2 (fr) Compositions antimicrobiennes et procédés d'utilisation associes.
SG10201901259RA (en) Prebiotic formulations and methods of use
MX2016001640A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
WO2010062396A3 (fr) Compositions de particule de type viral et procédés d'utilisation
MX2017009616A (es) Material de varilla para componentes de maquinas sin revenir, varillas de acero para componentes de maquinas sin revenir y componentes de maquinas sin revenir.
RS20080167A (en) Novel improved compositions for cancer therapy
EP2481402A3 (fr) Nanoparticule comportant du rapamycine et albumine en tant qu'agent anti-cancer
MY177537A (en) Production of encapsulated nanoparticles at commercial scale
MA33296B1 (fr) Nouvelle formulation d'indométhacine
MA34067B1 (fr) Composés à base de complexes de fe(iii) pour le traitement et la prévention des carences en fer et des anémies dues à une carence en fer
MX2013007535A (es) Composicion de relleno que comprende un aceite encapsulado.
MA38567A1 (fr) Variantes de pertuzumab et leur évaluation
WO2010008491A3 (fr) Compositions de lactose ayant une teneur réduite en lactose
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
WO2018119196A8 (fr) Immunoconjugués ciblant l'adam9 et leurs méthodes d'utilisation
MX2013011231A (es) Nanoparticulas basadas en lipidos.